Similar articles for PMID: 27121689

Year	Number of Results
1903	2
1909	7
1912	1
1914	1
1918	2
1921	1
1927	1
1929	1
1930	1
1933	2
1935	1
1936	1
1938	1
1995	1
2002	1
2003	1
2005	1
2006	1
2008	1
2012	7
2013	18
2014	21
2015	43
2016	35
2017	43
2018	36
2019	34
2020	27
2021	12
2022	11
2023	5
2024	0

1

Radium-223 dichloride in clinical practice: a review.

Florimonte L, Dellavedova L, Maffioli LS. Florimonte L, et al. Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1896-909. doi: 10.1007/s00259-016-3386-5. Epub 2016 Apr 28. Eur J Nucl Med Mol Imaging. 2016. PMID: 27121689 Review.

2

Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer.

Nilsson S. Nilsson S. Curr Oncol Rep. 2016 Feb;18(2):14. doi: 10.1007/s11912-015-0495-4. Curr Oncol Rep. 2016. PMID: 26779616 Free PMC article. Review.

3

Radium-223 in Metastatic Castration-Resistant Prostate Cancer: Clinical Development and Use in Contemporary Practice.

Morgan SC. Morgan SC. J Med Imaging Radiat Sci. 2019 Dec;50(4S1):S26-S30. doi: 10.1016/j.jmir.2019.05.006. Epub 2019 Jun 21. J Med Imaging Radiat Sci. 2019. PMID: 31231006 Review.

4

Radiometabolic treatment of bone-metastasizing cancer: from 186rhenium to 223radium.

Rubini G, Nicoletti A, Rubini D, Asabella AN. Rubini G, et al. Cancer Biother Radiopharm. 2014 Feb;29(1):1-11. doi: 10.1089/cbr.2013.1549. Epub 2013 Nov 1. Cancer Biother Radiopharm. 2014. PMID: 24180669 Review.

5

Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why.

Gallicchio R, Mastrangelo PA, Nardelli A, Mainenti PP, Colasurdo AP, Landriscina M, Guglielmi G, Storto G. Gallicchio R, et al. Tumori. 2019 Oct;105(5):367-377. doi: 10.1177/0300891619851376. Epub 2019 May 16. Tumori. 2019. PMID: 31096849 Review.

6

[Bone-specific therapy with radium-223 dichloride : Castration-resistant prostate cancer with symptomatic bone metastases].

Tauber R, Gschwend J, Scheidhauer K, Eiber M, Krönke M. Tauber R, et al. Urologe A. 2017 Jan;56(1):24-31. doi: 10.1007/s00120-016-0300-5. Urologe A. 2017. PMID: 28058455 German.

7

Integrating bone targeting radiopharmaceuticals into the management of patients with castrate-resistant prostate cancer with symptomatic bone metastases.

Blacksburg SR, Witten MR, Haas JA. Blacksburg SR, et al. Curr Treat Options Oncol. 2015 Mar;16(3):325. doi: 10.1007/s11864-014-0325-1. Curr Treat Options Oncol. 2015. PMID: 25777571 Review.

8

[Targeted radionuclide therapy for castration-resistant prostate cancer].

Nakamura K, Ohga S, Sasaki T, Baba S, Honda H. Nakamura K, et al. Nihon Rinsho. 2014 Dec;72(12):2181-5. Nihon Rinsho. 2014. PMID: 25518355 Review. Japanese.

9

Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.

Uemura H, Uemura H, Nagamori S, Wakumoto Y, Kimura G, Kikukawa H, Yokomizo A, Mizokami A, Kosaka T, Masumori N, Kawasaki Y, Yonese J, Nasu Y, Fukasawa S, Sugiyama T, Kinuya S, Hosono M, Yamaguchi I, Akagawa T, Matsubara N. Uemura H, et al. Int J Clin Oncol. 2019 May;24(5):557-566. doi: 10.1007/s10147-018-01389-4. Epub 2019 Mar 14. Int J Clin Oncol. 2019. PMID: 30875000 Free PMC article. Clinical Trial.

10

Radium-223 dichloride: a new paradigm in the treatment of prostate cancer.

Anido Herranz U, Fernández Calvo O, Afonso Afonso FJ, Rodríguez Martínez de Llano S, Lázaro Quintela M, León Mateos L, Vázquez Estévez S, Antón Aparicio LM. Anido Herranz U, et al. Expert Rev Anticancer Ther. 2015 Mar;15(3):339-48. doi: 10.1586/14737140.2015.999045. Epub 2015 Jan 2. Expert Rev Anticancer Ther. 2015. PMID: 25555355 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

283 results

Results by year